AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| AIM | AIM ImmunoTech Inc. | 2025-10-16 17:03:37 | 2.57 | -0.04 | -1.53 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AIM | 0000946644 | AIM ImmunoTech Inc. | US00901B3033 | — | 520845822 | NYSE | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 2117 SW HIGHWAY 484 | OCALA | FL | 32801 | UNITED STATES | US | 352-448-7797 | 2117 SW HIGHWAY 484, OCALA, FL, 32801 | 2117 SW HIGHWAY 484, OCALA, FL, 32801 | AIM ImmunoTech Inc. | Biopharmaceutical | — | — | — | — | 20,793,354 | 764,188 | 2,708,688 | AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees. | 2025-10-11 00:11:36 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 20,793,354 | -11,036,128 | -34.6727 | 72,290,030 | 22,388,853 | 44.8664 |
| 2023 | 31,829,482 | -4,425,001 | -12.2054 | 49,901,177 | 1,493,851 | 3.086 |
| 2022 | 36,254,483 | -64,859,757 | -64.145 | 48,407,326 | 412,654 | 0.8598 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Ellen Lintal | CFO | 2020 | 239,583 | 177,000 | 0 | 0 | 25,403 | 553,602 |
| Thomas K | CEO, President | 2019 | 703,125 | 7,008 | 46,875 | 0 | 70,702 | 883,239 |
| Ellen Lintal | CFO | 2019 | 143,750 | 0 | 10,417 | 0 | 33,575 | 187,742 |
| Adam Pascale | CFO | 2019 | 197,917 | 0 | 0 | 0 | 27,864 | 246,627 |
| Peter Rodino | Secretary, COO, General Counsel | 2019 | 333,333 | 0 | 21,875 | 0 | 45,710 | 430,102 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 170,000 | 202,000 | 141,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 6,197,000 | 10,939,000 | 6,990,000 |
| General And Administrative Expenses | 13,714,000 | 21,137,000 | 13,074,000 |
| Operating Expenses | 19,942,000 | 32,118,000 | 20,064,000 |
| Operating Income | -19,772,000 | -31,916,000 | -19,923,000 |
| Net Income | -17,320,000 | -28,962,000 | -19,445,000 |
| Earnings Per Share Basic | -0.31 | -0.6 | -0.4 |
| Earnings Per Share Diluted | -0.31 | -0.6 | — |
| Weighted Average Shares Outstanding Basic | 56,016,870 | 48,270,000 | 48,612,500 |
| Weighted Average Shares Outstanding Diluted | 56,016,870 | 48,585,404 | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 1,701,000 | 5,439,000 | 27,053,000 |
| Marketable Securities Current | 2,276,000 | 7,631,000 | 7,137,000 |
| Accounts Receivable | — | 1,184,000 | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 4,176,000 | 14,556,000 | 36,321,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 108,000 | 127,000 | 195,000 |
| Other Assets Non Current | 1,112,000 | 1,688,000 | 1,202,000 |
| Total Assets Non Current | 4,432,000 | 4,825,000 | 4,167,000 |
| Total Assets | 8,608,000 | 19,381,000 | 40,488,000 |
| Accounts Payable | 6,383,000 | 6,443,000 | 377,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 2,307,000 | — | — |
| Other Liabilities Current | 606,000 | 1,986,000 | 806,000 |
| Total Liabilities Current | 9,535,000 | 8,652,000 | 1,361,000 |
| Long Term Debt | 2,807,000 | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 395,000 | 495,000 | — |
| Total Liabilities | 9,930,000 | 9,147,000 | — |
| Common Stock | 66,000 | 49,000 | 48,000 |
| Retained Earnings | -426,828,000 | -409,508,000 | -380,546,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | -1,322,000 | 10,234,000 | 38,468,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 302,000 | 39,000 | 38,000 |
| Share Based Compensation Expense | 686,000 | 243,000 | 954,000 |
| Other Non Cash Income Expense | — | 18,000 | 3,000 |
| Change In Accounts Receivable | -1,184,000 | -492,000 | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | 35,000 |
| Change In Other Assets | -576,000 | 486,000 | 83,000 |
| Change In Accounts Payable | -60,000 | 6,066,000 | 179,000 |
| Change In Other Liabilities | -1,198,000 | 1,180,000 | 368,000 |
| Cash From Operating Activities | -14,888,000 | -21,267,000 | -16,108,000 |
| Purchases Of Marketable Securities | 361,000 | 1,593,000 | 2,724,000 |
| Sales Of Marketable Securities | 663,000 | — | 10,083,000 |
| Acquisition Of Property Plant And Equipment | 18,000 | — | 86,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 4,706,000 | -832,000 | 10,988,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 131,000 | 150,500 | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 6,444,000 | 485,000 | 80,000 |
| Change In Cash | -3,738,000 | -21,614,000 | -5,040,000 |
| Cash At End Of Period | 1,701,000 | 5,439,000 | 27,053,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 585,000 | — | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -0.31 | -0.6 | -0.4 |
| Price To Earnings Ratio | -63.871 | -73.3167 | -77.975 |
| Earnings Growth Rate | -48.3333 | 50 | — |
| Price Earnings To Growth Ratio | 1.3215 | -1.4663 | — |
| Book Value Per Share | -0.0236 | 0.212 | 0.8049 |
| Price To Book Ratio | -838.9819 | 207.4846 | 38.7513 |
| Ebitda | -16,433,000 | -28,923,000 | -19,407,000 |
| Enterprise Value | 1,112,547,026 | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -3.8684 | — | — |
| Capital Expenditures | 283,000 | -29,000 | -3,814,000 |
| Free Cash Flow | -15,171,000 | -21,238,000 | -12,294,000 |
| Return On Equity | 13.1014 | -2.83 | -0.5055 |
| One Year Beta | 0.7696 | 1.4436 | 0.6921 |
| Three Year Beta | 0.8451 | 0.8478 | -0.5875 |
| Five Year Beta | -0.3408 | -0.3395 | -0.3744 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Equels Thomas K | Director, CEO & President | 2025-06-13 | 107 | A | 38,885 |
| Equels Thomas K | Director, CEO & President | 2025-06-12 | 103 | A | 38,675 |
| KELLNER TED D | Director | 2025-04-11 | 1,968,504 | A | 1,969,504 |
| Equels Thomas K | Director, CEO & President | 2025-04-11 | 1,968,504 | A | 3,867,533 |
| MITCHELL WILLIAM M | Director | 2025-04-11 | 196,851 | A | 521,723 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Farther Finance Advisors, LLC | 2025-09-30 | 3 | 1 | 3 |
| Corient Private Wealth LLC | 2025-06-30 | 86,509 | 10,001 | 8.65 |
| OSAIC HOLDINGS, INC. | 2025-06-30 | 86 | 10 | 8.6 |
| MORGAN STANLEY | 2025-06-30 | 6,591 | 762 | 8.6496 |
| BANK OF AMERICA CORP /DE/ | 2025-06-30 | 43 | 5 | 8.6 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| AMERICAN CENTURY ETF TRUST | 2025-05-31 | Avantis Responsible International Equity ETF | AVSD | 986 | 1,968.62 | 0.0011 |
| AMERICAN CENTURY ETF TRUST | 2025-05-31 | Avantis International Equity ETF | AVDE | 5,405 | 10,791.49 | 0.0002 |
| AMERICAN CENTURY ETF TRUST | 2025-02-28 | Avantis Responsible International Equity ETF | AVSD | 986 | 1,703.82 | 0.0011 |
| AMERICAN CENTURY ETF TRUST | 2025-02-28 | Avantis International Equity ETF | AVDE | 5,405 | 9,339.9 | 0.0002 |
| VANGUARD INDEX FUNDS | 2024-12-31 | Institutional Select Shares | VSEMX | 620,229 | 122,805.34 | 0.0001 |